In 2023, Alexa was diagnosed with primary myelofibrosis (a rare bone marrow condition) and will require a stem cell transplant.

If you are between the ages of 17-35, please consider joining the stem cell registry at ow.ly/wnsb50RHpBB

🚨 SAVE THE DATE 🚨
New GATMO webinar!
On this occasion we have the honor of having Dr. Gagelmann Nico Gagelmann in the management of myelofibrosis in patients who are candidates for transplant.
Sociedad Argentina de Hematología
Non-fee activity
Link: soon

So my mom got a bone marrow/stem cell transplant today which is like you know kinda cool.

#BeTheMatch
#FuckCancer
#Myelofibrosis

📙𝘾𝙇𝙄𝙉𝙄𝘾𝘼𝙇_𝙌𝙐𝙄𝙕:-

📝A 40yr old male from Italy p/w hemoglobinuria,fatigue,sudden development of yellowish skin.He gave h/o eating of fava beans.

Diagnosis ❓

1️⃣ Myelofibrosis
2️⃣ Gilbert syndrome
3️⃣ G6PD deficiency
4️⃣ Sickel cell anemia

#medx

🎉Finally out🎉

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing transplantation

👉Treosulfan and busulfan in reduced dose are similarly effective and superior to higher doses

#mpnsm AmericanJournalofHematology

doi.org/10.1002/ajh.27…

Very excited that I will be presenting our work on developing a novel CAR T for MF at #EHA24 in Madrid

DEVELOPMENT AND EVALUATION OF A NOVEL CAR-T CELL THERAY FOR CALRETICULIN MUTATED MYELOFIBROSIS
EHA Library; Jun 13 2024; 422320
library.ehaweb.org/eha/2024/eha20…

If you would like to help amore with her rare bone marrow cancer (myelofibrosis) journey, please consider donating.

All proceeds go to her to help with her day to day needs. We appreciate any help. It is a difficult situation.

All information on the foundation is on the

AEL transformed from post-ET myelofibrosis with a sinusoidal pattern, JAK2 mutation, and biallelic TP53 inactivation
ow.ly/Nj9U50RIL7r #bloodwork #myeloidneoplasia

Essential Thrombocythemia Complications!

1. Vascular = 15-year risk of thrombosis 10%-25%, ⬆️JAK2 than in CALR mutated.
2. Progression to myelofibrosis = 15-year risk 10%, ⬆️type 1 (not type 2) CALR-mutant than in JAK2-mutant ET.
3. Leukemic transformation (15-year = 3%).

Ongoing research in myelofibrosis continues to focus on agents directed at novel targets with the hope of expanding treatment options beyond the host of JAK inhibitors used in this treatment paradigm. Winship Cancer Institute of Emory University #oncology #mpnsm onclive.com/view/novel-tar…

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
buff.ly/3UbndjJ

📢Our latest IACH webinar:

Allogeneic Stem Cell Transplantation for Myelofibrosis

📽️Now available on demand
Watch the full library for FREE
🔽🔽
clinical-hematology.org/video-library/

Mohamad Mohty

New endpoints in #myelofibrosis ‼️
A provocative 👀 topic by Naveen Pemmaraju, MD at the #MPN #MDS meeting #leusm

#weekend_review 🧵
1/6 Myelofibrosis after failure of Ruxolitinib

JAK inhibitors are incorporated into management for splenomegaly and improved QOL from symptom improvement.

50% of patients discontinue treatment @ 3 years and 75% @ 5 yrs, as per data from COMFORT-I and II

What is #Myelofibrosis ? What Were My First Symptoms? Part One!
youtu.be/nFp7dc2XRsg

Don’t forget to subscribe for updates on my journey !

#Autoimmune #myelofibrosis : A Mayo Clinic series of 22 patients
doi.org/10.1111/bjh.19…
#MPNsm

TAFRO syndrome with a fatal clinical course following 2nd #Pfizer #mRNA vaccine.

42-year-old Japanese man dead

The patient had a low platelet count, ascites, reticulin myelofibrosis, renal failure, and lymphadenopathy and was diagnosed with TAFRO syndrome.

Very glad to present our data on pre-clinical validation for the discovery of a novel CAR-T therapy for mutCALR Myelofibrosis in such an amazing meeting #ESHMPN2024

Many thanks to Claire Roddie, Martin Pule, Jon Lambert and Beth Psaila for their ongoing support

UCL Cancer Institute

When the #ManOfTheDay #Co -Chair of MPN-MDS US focus meeting MD Education hits the stage !! The one and only Prithviraj Bose can publish and decipher this figure 😊 #MPNsm awesome session, #novel agents made easy #Myelofibrosis

At the upcoming #ASCO24 annual meeting, we’re presenting new efficacy and safety data from our Phase 3 MANIFEST-2 trial evaluating our investigational BET inhibitor in combination with a JAK inhibitor in #myelofibrosis . Learn more: bit.ly/3U9VujH